More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$116406425
EPS
-3.27
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
1.489936
Previous close
$7.23
Today's open
$7.26
Day's range
$7.06 - $7.48
52 week range
$5.06 - $17.43
show more
CEO
Erik Lundgren
Employees
100
Headquarters
New York, NY
Exchange
NASDAQ Capital Market
Shares outstanding
15880822
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – – Initiation of Phase 3 PROTECT-MS Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Ongoing, with First-Patient-Enrolled Expected in the First Half of 2027 – – Executive Leadership Team Further Strengthened with Appointments of Chief Data and Digital Officer and Chief People Officer to Support Regulatory and Commercial Readiness – NEW YORK, Nov. 13, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. "As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history," said Erik Lundgren, Chief Executive Officer of Immunic.
PRNewsWire • Nov 13, 2026

Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development Transcript
Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development Transcript
Seeking Alpha • Nov 10, 2026

Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
Immunic NASDAQ: IMUX is preparing a Phase 3 trial of its experimental multiple sclerosis drug vidofludimus calcium in progressive disease, with the first patients expected to enroll in the first half of 2027.
MarketBeat • Nov 6, 2026

Immunic to Participate in Investor Conferences in November
NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November: November 9-11: Guggenheim 3rd Annual Healthcare Innovation Conference. Erik Lundgren, Chief Executive Officer, and Jason Tardio, President and Chief Operating Officer, will participate in a fireside chat on Monday, November 9, 2026 at 1:00 pm ET at this conference in Boston.
PRNewsWire • Nov 2, 2026

Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET. In addition to members of Immunic's management team, including Erik Lundgren, M.B.A.
PRNewsWire • Oct 29, 2026

New Strong Buy Stocks for October 22nd
BBCP, UCB, TGS, STX and IMUX have been added to the Zacks Rank #1 (Strong Buy) List on October 22, 2026.
Zacks Investment Research • Oct 22, 2026

Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared Consistent With That Observed in the Double-Blind Period – – New Preclinical Data Suggest Nurr1-Dependent Neuronal Survival and Neuroprotective Effects Beyond DHODH Inhibition – – Exploratory and Post-hoc CALLIPER Analyses Show Significant Reductions in EBV-Specific T-Cell Receptor Signatures; Observed Reductions Associated With Increased Symbol Digit Modalities Test (SDMT) Scores – – Post-hoc Analysis of CALLIPER Using a Proposed Novel Disability Measure Suggests Overall Benefit of Vidofludimus Calcium in Progressive Multiple Sclerosis Patients – NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that new clinical, biomarker, and preclinical data for its lead investigational asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), are being presented across four poster presentations at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, taking place October 21-23, 2026, in Toronto. All posters are available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
PRNewsWire • Oct 21, 2026

Immunic adds new Chief People Officer ahead of Phase 3 readout
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has appointed Jaa Roberson as its first Chief People Officer, adding a senior human resources leader as the biotechnology company prepares for a pivotal multiple sclerosis trial readout expected by the end of 2026. Roberson will report to CEO Erik Lundgren and join the executive leadership team.
Proactive Investors • Oct 19, 2026

Immunic Appoints Jaa Roberson as Chief People Officer
– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company – NEW YORK, Oct. 19, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jaa Roberson as Chief People Officer (CPO), effective today. Ms. Roberson will report directly to Chief Executive Officer Erik Lundgren and will serve as a member of the executive leadership team.
PRNewsWire • Oct 19, 2026

Immunic to present four vidofludimus calcium abstracts at MSToronto2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said four abstracts on its lead MS drug candidate, vidofludimus calcium, have been accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto from October 21 to 23. The oral therapy is a Nurr1 activator under development for neurologic diseases.
Proactive Investors • Oct 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Immunic Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.